This population-based study investigated the incidence and trends in venous thromboembolic disease after total hip and knee arthroplasty over a ten-year period. Death or readmission for venous thromboembolic disease up to two years after surgery for all patients in Scotland was the primary outcome. The incidence of venous thromboembolic disease, including fatal pulmonary embolism, three months after surgery was 2.27% for primary hip arthroplasty and 1.79% for total knee arthroplasty. The incidence of fatal pulmonary embolism within three months was 0.22% for total hip arthroplasty and 0.15% for total knee arthroplasty. The majority of events occurred after hospital discharge, with no apparent trend over the period. The data support current advice that prophylaxis should be continued for at least six weeks following surgery. Despite the increased use of policies for prophylaxis and earlier mobilisation, there has been no change in the incidence of venous thromboembolic disease.
This population-based study investigated the incidence and trends in venous thromboembolic disease after total hip and knee arthroplasty over a ten-year period. Death or readmission for venous thromboembolic disease up to two years after surgery for all patients in Scotland was the primary outcome. The incidence of venous thromboembolic disease, including fatal pulmonary embolism, three months after surgery was 2.27% for primary hip arthroplasty and 1.79% for total knee arthroplasty. The incidence of fatal pulmonary embolism within three months was 0.22% for total hip arthroplasty and 0.15% for total knee arthroplasty. The majority of events occurred after hospital discharge, with no apparent trend over the period. The data support current advice that prophylaxis should be continued for at least six weeks following surgery. Despite the increased use of policies for prophylaxis and earlier mobilisation, there has been no change in the incidence of venous thromboembolic disease.
Venous thromboembolism as a complication of total hip arthroplasty (THA) is the greatest potentially preventable threat to life. 1 Without prophylaxis, reported rates of deep venous thrombosis (DVT) vary between 40% and 60%. Proximal vein thrombosis is thought to be more clinically relevant, with a prevalence of 20% to 40%. 2 The rate of symptomatic pulmonary embolism is between 0.76% and 1.5%, with a mortality rate between 0.19% 3 and 0.4%. 4 Pharmacological and mechanical prophylaxis is recommended in high-risk patients. Guidelines for protection against venous thromboembolic disease in Scotland in 1995 suggested low-dose aspirin and low molecular weight heparin or oral anticoagulants, along with mechanical methods such as graduated stockings or intermittent pressure devices. 5 Worldwide debate on optimal chemical prophylaxis continues. 1, [5] [6] [7] Several meta-analyses have evaluated methods of prophylaxis, mainly chemical, for hip and knee replacement. [8] [9] [10] [11] [12] Guidelines or consensus statements based on this and other evidence, such as the pulmonary embolism protection trial, 13 promoted the use of and need for specific prophylaxis. However, there is scepticism as to whether the end-points are valid. Criticisms relate to diagnostic methods, under-reporting, emphasis on bleeding and wound complications, especially haematomas and the short-term follow-up, which is often only until discharge from hospital. It is also important to consider when thrombosis is clinically important in terms of effect size and estimates of risk. 14, 15 Throughout the NHS in Scotland the hospital-based Scottish Morbidity Record (SMR01) system (NHS National Services, Scotland) collects summary information for each in-patient or day-case episode, and whether it is terminated by discharge from hospital, change of specialty or death. Clinical data identify the main condition treated and up to four co-morbidities, which include complications. By linking SMR01 records to each other and to the Registrar General's death records, it is possible to estimate the number of complications after specific operations.
As all operations are recorded in SMR01, other procedures can be explored similarly. We selected patients with cataract surgery as our control population, assuming that they are ambulant, the operation is not associated with a major risk of venous thromboembolic disease, and that the age range is similar to that in arthroplasty. Analysis of such patients would provide baseline data for venous thromboembolic disease.
The aim of this study was to examine the trends and timing of thromboembolic complications and fatal pulmonary embolism after lower limb arthroplasty over a ten-year period. Our objectives were to detect any change in the incidence of death or readmission after hip or knee replacement due to venous thromboembolic disease, to compare these rates with those after cataract surgery and to compare the rates of venous thromboembolic disease between primary hip or knee arthroplasty and revision arthroplasty.
Method
The SMR01 system was used to identify all patients undergoing hip or knee arthroplasty between 1992 and 2001. Patients undergoing cataract surgery during the same period were identified as a control group. Details of further admissions for venous thromboembolic disease or nonfatal pulmonary embolism in Scotland for up to two years after the operation were provided by linking patient records with subsequent SMR01 and Registrar General records. From the latter we determined the cause of death in each case and selected those where venous thromboembolic disease was the primary or a contributing cause of death.
Information was collected on age, gender, type of surgery (hip/knee/cataract, revision/primary), day-case or in-patient stay and time to venous thromboembolic disease or death. The interval between the initial operation and the first recording of venous thromboembolic disease, whether on SMR01 or a death record, was calculated. If the event was in the SMR01 record of the initial operation, the interval could not be determined because operations are dated whereas diagnoses are not. For venous thromboembolic disease identified in a subsequent linked SMR01 or record of death, the interval was the time between the initial operation and the date of admission or death on the subsequent record. The resulting intervals were grouped as less than six weeks; six weeks to three months; three months to one year; and more than a year.
From the SMR01 records, if a patient underwent more than one procedure, the interval was calculated from the nearest preceding operation date.
The primary outcomes reported here are symptomatic venous thromboembolic disease, including non-fatal and fatal pulmonary embolism, from death certification up to 90 and 365 days after the operation. The total number of deaths and deaths due to acute myocardial infarction and cerebrovascular accident are also reported.
A total of 44 785 hip replacements, 27 503 knee replacements and 176 520 cataract operations were performed in Scotland between 1992 and 2001 (Table I) . Cataract patients were slightly older (mean age 74 years) than those undergoing arthroplasty (hip patients with mean age of 68 years and knee patients with mean age of 69 years). Maleto-female ratios were similar in all groups.
Analysis of data was by SPSS (version 11.5; SPSS Inc., Chicago, Illinois). Logistic regression identified which factors had a significant predisposition to venous thromboembolic disease. All variables thought to influence the development of venous thromboembolic disease were fitted to the regression model. Those with a significance level of p ≤ 0.05 would affect a patient's chances of developing venous thromboembolic disease other than by chance.
Results
The incidence of symptomatic venous thromboembolic disease and fatal pulmonary embolism up to 90 and 365 days after the operation is shown in Table II . The incidence of venous thromboembolic disease up to 90 days following surgery appears higher after hip arthroplasty than after knee arthroplasty, and both have a significantly higher (p < 0.001) incidence than after cataract surgery (odds ratio 14.8 for hip (95% confidence interval (CI) 12.9 to 16.9 and 11.62 for knee (95% CI 10.0 to 13.5). After three months, there is no difference in the rate of venous thromboembolic disease between arthroplasty and cataract cases. The proportion of day-case cataract operations has risen from 1% in 1992 to > 75% in 2001. Table III shows a comparison of venous thromboembolic disease between in-patient and day-case surgery for cataracts. Although the incidence is very low, there is a significant risk reduction for venous thromboembolic disease up to 90 days after daycase compared with in-patient care (odds ratio 0.49; 95% CI 0.36 to 0.66; p < 0.001).
To follow trends over time, data on DVT and non-fatal pulmonary embolism occurring within three months of surgery are shown in both Table I and Figure 1 . Using SMR01, it is possible to identify primary and revision arthroplasty. Table IV shows the amalgamated incidence between 1992 and 2001. The incidence of venous thromboembolic disease following revision surgery is significantly lower (p < 0.05) within 90 days of hip and knee arthroplasty, with odds ratios of 0.81 (95% CI 0.67 to 0.98) and 0.60 (95% CI 0.39 to 0.92), respectively. Patients of 60 years are at a greater risk (p < 0.01), with an odds ratio of 1.32 (95% CI 1.12 to 1.56) for hips and 1.74 (95% CI 1.25 to 2.43) for knees. The same pertains for cataract surgery (odds ratio 1.65; 95% CI 1.02 to 2.67; p < 0.05).
The annual incidence of death due to acute myocardial infarction, cerebrovascular accident and pulmonary embolism up to 90 days after surgery is shown in Table V . Up to 365 days the total death rate is highest in the cataract group (Fig. 2) , most likely because of their more advanced age. Incidence of symptomatic venous thromboembolic disease (excluding fatal pulmonary embolism) over time by type of operation. Also, the arthroplasty group are selected as deemed fit to survive a major elective operation. The annual trend shows a reduction in the total death rate for all procedures, apparently owing to an annual reduction in acute myocardial infarction (Fig. 3) There is a reduction in deaths from cerebrovascular accident in the cataract group but not in the arthroplasty group, in whom the annual incidence of fatal cerebrovascular accident is already lower (Fig. 4) . There is no difference in the rate of fatal pulmonary embolism at 90 or 365 days after arthroplasty (Figs 3 and 5) . The risk of fatal pulmonary embolism after lower limb arthroplasty is significantly higher than for cataract cases with the majority of deaths occuring between discharge and six weeks post-operatively. Many events occur outside the arthroplasty episode, indicating that death followed either transfer to another specialty, readmission with venous thromboembolic disease after discharge, or occurred outside hospital. Venous thromboembolic disease-related death rates varied during the study period (Figs 5 and 6) . In 1992 the death rate was double that of subsequent years. The reason for this is unclear. There were no identifiable campaigns in this period to significantly alter thromboprophylactic practices. We believe that this reported increase is due to an increased awareness of pulmonary embolism, following publication of an article in the British Medical Journal . 16 This highlights a potential drawback in using the certified cause of death rather than post mortem diagnosis in our study. There are no detectable trends, although the rates may show a tendency to stabilise at a relatively low level. The average rate of fatal pulmonary embolism within three months is slightly less after TKA (0.15%) than after hip arthroplasty (0.22%). This difference is statistically significant (odds ratio 0.67; 95% CI 0.46 to 0.97; p < 0.05) and both are far in excess of fatal pulmonary embolism for cataract surgery.
Discussion
Complications recorded in SMR01 should be those that require specific care or which affect the general management of the patient. Their incidence will therefore represent more severe, clinically obvious disorders, and be significantly lower than those derived from screening techniques such as venography or isotope scanning. In this study, the Incidence of fatal acute myocardial infarct up to 365 days post-operatively by type of operation incidence of venous thromboembolic disease was not restricted to events within ten days of surgery, and therefore reflects its effect on the healthcare system. Although there may be under-recording of thromboembolic complications, the linked data set gives a reasonable estimate of the incidence of serious clinical disease. Also, previous studies 17 have shown good correlation with SMR01 data.
Whereas the certification of death because of pulmonary embolism may be criticised because of the low incidence of autopsy (< 10% in this study), our rate of fatal pulmonary embolism at 90 days after THA was 0.22%, which compares well with other studies, 18, 19 as does our incidence of death due to acute myocardial infarction after arthroplasty. 5, 20 Our incidence (1.79%) of readmission for DVT or pulmonary embolism after primary TKA reflects clinically significant episodes and is therefore lower than other indicators, such as venography. However, our incidence (2.27%) of readmission for DVT or pulmonary embolism after primary THA is comparable to that in similar studies. 6 Most post-operative thrombi undergo spontaneous lysis 14, 21 and radiologically demonstrated venous thromboembolism may not equate to subsequent clinical events. 22 Subclinical venous thromboembolism with subsequent post-thrombotic syndrome does not usually become clinically evident for many years. Therefore, we consider that, despite methodological problems (general practitioner death certificate diagnosis of pulmonary embolism, definition of clinically significant DVT on admission and the use of an administrative database), our figures represent the true cost to society.
Interpretation of the interval between operation and a significant event is difficult because the onset of venous thromboembolic disease during this episode is not recorded. Furthermore, the next category used (less than six weeks post-operatively) includes three types of patient, namely those transferred to intensive care or medical units, those readmitted with thromboembolism and those who died during this period.
The first two intervals are best considered as a six-week continuum of diagnosis. Whereas the majority of patients are discharged from hospital prior to the development of symptomatic venous thromboembolic disease, contemporary prevention regimes are recommended only for the period in hospital. Previous population-based studies have reported insufficient evidence for extended thromboprophylaxis. 5 Our data indicate that patients are at increased risk of venous thromboembolic disease for three months after surgery. These observations are not new, 6 indeed, short-term prophylaxis using mechanical stimulation or heparin may delay the onset of DVT and/or pulmonary embolus after THA. 23 Reflex thrombophilia can occur after chemical prophylaxis, 24, 25 and our figures support the proposal that DVT prophylaxis should be continued for a minimum of six weeks and possibly three months, postoperatively. Furthermore, studies of the efficacy of prophylaxis should be for at least six weeks after surgery and a further six weeks after treatment. The overall follow-up should be at least one year. The validity of studies of thromboprophylactic regimens with outcomes measured before discharge or at the termination of active prophylaxis should be questioned.
The absence of any significant change in the incidence of venous thromboembolic disease and fatal pulmonary embolism over the ten-year period is interesting, particularly in the context of changes in DVT prophylaxis. At the beginning of this study, a review among orthopaedic surgeons showed that less than 50% used routine chemical prophylaxis. 26 An identical review after the introduction of guidelines in 1996 showed that 80% used some form of such treatment. 27 Although it is uncertain that adequate prophylaxis was used in all cases and that chemical prophylaxis was probably discontinued on discharge, we cannot show a change in the rate of readmission or death due to venous thromboembolic disease that reflects this. Similarly, early mobilisation would show a reduced incidence of venous thromboembolic disease, 28 but this was not detectable. These findings should be interpreted with caution and do not imply that anti-thrombotic prophylaxis and earlier mobilisation regimens have no effect.
Another surprising finding is that patients undergoing revision arthroplasty had a slight but statistically significantly smaller risk of venous thromboembolic disease than those having primary surgery. This contradicts the belief that longer time on the operating table and in bed postoperatively increases the risk of venous thromboembolic disease. Patient selection may explain this finding. For example, those with thrombophilia may have been excluded from revision arthroplasty because of previous venous thromboembolic disease. Alternatively, it could be related to the experience of the surgeon. Revision procedures tend to be performed by surgeons with a high throughput of primary arthroplasties who have a lower rate of venous thromboembolic disease after primary procedures. 29 No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.
